CD33 and colorectal carcinoma: There was no difference in expression levels of CD33+CD11b+HLA-DR−/lowCD15+ cells between patients with low-grade tumors and HDs (Figure 4C), but these cells expressed significantly higher levels of ARG1 in low-grade CRC patients compared with HDs (Figure 4D).